Erlotinib in glioblastoma - lost in translation?

Anti-Cancer Agents in Medicinal Chemistry

Volumn 11, Issue 8, 2011, Pages 748-755

  Karpel Massler, Georg ^a   Westhoff, M Andrew ^a   Kast, Richard E ^b   Wirtz, Christian Rainer ^a   Halatsch, Marc Eric ^a  

^a UNIVERSITY OF ULM   (Germany)

^b UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

Clinical trials; Combination therapy; Erlotinib; Glioblastoma; HER1 EGFR; Small molecule tyrosine kinase inhibitors

Indexed keywords

BEVACIZUMAB; CANCER VACCINE; CARBOPLATIN; CARMUSTINE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; IRINOTECAN; LOMUSTINE; PEP 3 KLH; PROCARBAZINE; RAPAMYCIN; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANTIBODY RESPONSE; ANTINEOPLASTIC ACTIVITY; BRAIN HEMORRHAGE; BRAIN RADIATION; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CELL VIABILITY; CHEMORADIOTHERAPY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; GENE EXPRESSION; GLIOBLASTOMA; HEALTH CARE QUALITY; HUMAN; INTRACRANIAL TUMOR; MELANOMA; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; NONHUMAN; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; UNSPECIFIED SIDE EFFECT;

EID: 80053557029     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/187152011797378788     Document Type: Review

References (68)

1. Wells, A. EGF receptor. Int. J. Biochem. Cell Biol., 1999, 31, 637-643.
2. Arteaga, C. HER1/EGFR: a molecular approach to cancer therapy. Semin. Oncol., 2003, 30, 3-14.
3. Scagliotti, G.; Selvaggi, G.; Novello, S.; Hirsch, F. The biology of epidermal growth factor receptor in lung cancer. Clin. Cancer Res., 2004, 10, 4227s-4232s.
4. Earp, H.; Calvo, B.; Sartor, C. The EGF receptor family - multiple roles in proliferation, differentiation, and neoplasia with an emphasis on HER4. Trans. Am. Clin. Climatol. Assoc., 2003, 114, 315-333.
5. Halatsch, M.-E.; Schmidt, U.; Behnke-Mursch, J.; Unterberg, A.; Wirtz, C. Epidermal growth factor receptor inhibition for the treatment of glioblastoma multiforme and other malignant brain tumours. Cancer Treat Rev., 2006, 32, 74-89.
6. Salomon, D.; Brandt, R.; Ciardello, F.; Normanno, N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol. Hematol., 1995, 19, 183-232.
7. Frederick, L.; Wang, X.-Y.; Eley, G.; James, C. Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res., 2000, 60, 1383-1387.
8. Karpel-Massler, G.; Wirtz, C.; Halatsch, M.-E. Ribozyme-mediated inhibition of 801-bp deletion-mutant epidermal growth factor receptor mRNA expression in glioblastoma multiforme. Molecules, 2010, 15, 4670-4678.
9. Nishikawa, R.; Ji, X.; Harmon, R.; Lazar, C.; Gill, G.; Cavenee, W.; Huang, H. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc. Natl. Acad. Sci. USA, 1994, 91, 7727-7731.
10. Karpel-Massler, G.; Schmidt, U.; Unterberg, A.; Halatsch, M.E. Therapeutic inhibition of the epidermal growth factor receptor in high-grade gliomas - where do we stand? Mol. Cancer Res., 2009, 7, 1000-1012.
11. Reardon, D.A.; Wen, P.Y. Therapeutic advances in the treatment of glioblastoma: rationale and potential role of targeted agents. Oncologist, 2006, 11, 152-164.
12. Stupp, R.; Mason, W.; van den Bent, M.; Weller, M.; Fisher, B.; Taphoom, M.; Belanger, K.; Brandes, A.; Marosi, C.; Bogdahn, U.; Curschmann, J.; Janzer, R.; Ludwin, S.; Gorlia, T.; Allgeier, A.; Lacombe, D.; Cairncross, J.; Eisenhauer, E.; Mirimanoff, R. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J.Med., 2005, 352, 987-996.
13. Walker, M.; Green, S.; Byar, D.; Alexander, E.J.; Batzdorf, U.; Brooks, W.; Hunt, W.; MacCarty, C.; Mahaley, M.J.; Mealey, J.J.; Owens, G.; Ransohoff, J 2nd; Robertson, J.; Shapiro, W.; Smith, K.J.; Wilson, C.; Strike, T. Randomized comparison of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N. Engl. J. Med., 1980, 303, 1323-1329.
14. Rodriguez, L.; Prados, M.; Silver, P.; Levin, V. Reevaluation of procarbazine for the treatment of recurrent malignant central nervous system tumors. Cancer, 1989, 64, 2420-2423.
15. Newton, H.; Junck, L.; Bromberg, J.; Page, M.; Greenberg, H. Procarbazine chemotherapy in the treatment of recurrent malignant astrocytomas after radiation and nitrosourea failure. Neurology, 1990, 40, 1743-1746.
16. Brandes, A.; Tosoni, A.; Amista, P.; Nicolardi, L.; Grosso, D.; Berti, F.; Ermani, M. How effective is BCNU in recurrent glioblastoma in the modern era? A phase II trial. Neurology, 2004, 63, 1281-1284.
17. Raymond, E.; Fabbro, M.; Boige, V.; Rixe, O.; Frenay, M.; Vassal, G.; Faivre, S.; Sicard, E.; Germa, C.; Rodier, J.; Vernillet, L.; Armand, J. Multicenter phase II study and pharmakokinetic analysis of irinotecan in chemotherapy-naive patients with glioblastoma. Ann. Oncol., 2003, 14, 603-614.
18. Reardon, D.; Quinn, J.; Vredenburgh, J.; Rich, J.; Gururangan, S.; Badruddoja, M.; Herndon, J.E. 2nd; Dowell, J.; Friedman, A.; Friedman, H. Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma. Cancer, 2005, 103, 329-338.
19. Stark-Vance, V. Bevacizumab and CPT-11 in the treatment of relapsed malignant glioma. Neurooncol., 2005, 7, 369.
20. Vredenburgh, J.J.; Desjardins, A.; Herndon, J.E. 2nd; Marcello, J.; Reardon, D.A.; Quinn, J.A.; Rich, J.N.; Sathornsumetee, S.; Gururangan, S.; Sampson, J.; Wagner, M.; Bailey, L.; Bigner, D.D.; Friedman, A.H.; Friedman, H.S. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J. Clin. Oncol., 2007, 25, 4722-4729.
21. Chen, W.; Delaloye, S.; Silverman, D.; Geist, C.; Czernin, J.; Sayre, J.; Satyamurthy, N.; Pope, W.; Lai, A.; Phelps, M.; Cloughesy, T. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. J. Clin.Oncol., 2007, 25, 4714-4721.
22. Friedman, H.; Prados, M.; Wen, P.; Mikkelsen, T.; Schiff, D.; Abrey, L.; Yung, W.; Paleologos, N.; Nicholas, M.; Jensen, R.; Vredenburgh, J.; Huang, J.; Zheng, M.; Cloughesy, T. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J. Clin. Oncol., 2009, 27, 4733-4740.
23. Cloughesy, T.; Vredenburgh, J.; Day, B.; Das, A.; Friedman, H. Updated safety and survival of patients with relapsed glioblastoma treated with bevacizumab in the BRAIN study. J. Clin. Oncol., 2010, 28, 181s.
24. Lai, A.; Tran, A.; Nghiemphu, P.; Pope, W.; Solis, O.; Selch, M.; Filka, E.; Yong, W.; Mischel, P.; Liau, L.; Phuphanich, S.; Black, K.; Peak, S.; Green, R.; Spier, C.; Kolevska, T.; Polikoff, J.; Fehrenbacher, L.; Elashoff, R.; Cloughesy, T. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J. Clin. Oncol, 2011, 29, 142-148.
25. Lund-Johansen, M.; Bjerkvig, R.; Humphrey, P.; Bigner, S.; Bigner, D.; Laerum, O. Effect of epidermal growth factor on glioma cell growth, migration, and invasion in vitro. Cancer Res., 1990, 50, 6039-6044.
26. Shinojima, N.; Tada, K.; Shiraishi, S.; Kamiryo, T.; Kochi, M.; Nakamura, H.; Makino, K.; Saya, H.; Hirano, H.; Kuratsu, J.; Oka, K.; Ishimaru, Y.; Ushio, Y. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res., 2003, 63, 6962-6970.
27. Batra, S.; Castelino-Prabhu, S.; Wikstrand, C.; Zhu, X.; Humphrey, P.; Friedman, H.; Bigner, D. Epidermal growth factor ligandindependent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene. Cell Growth Differ., 1995, 6, 1251-1259.
28. Biernat, W.; Huang, H.; Yokoo, H.; Kleihues, P.; Ohgaki, H. Predominant expression of mutant EGFR (EGFRvIII) is rare in primary glioblastomas. Brain Pathol., 2004, 14, 131-136.
29. Nagane, M.; Coufal, F.; Lin, H.; Bögler, O.; Cavenee, W.; Huang, H. A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis. Cancer Res., 1996, 56, 5079-5086.
30. Klingler-Hoffmann, M.; Bukczynska, P.; Tiganis, T. Inhibition of phosphatidylinositol 3-kinase signaling negates the growth advantage imparted by a mutant epidermal growth factor receptor on human glioblastoma cells. Int. J. Cancer, 2003, 105, 319-331.
31. Moscatello, D.; Holgado-Madruga, M.; Emlet, D.; Montgomery, R.; Wong, A. Constitutive activation of phosphatidylinositol 3-kinase by a naturally occurring mutant epidermal growth factor receptor. J. Biol. Chem., 1998, 273, 200-206.
32. Klingler-Hoffmann, M.; Fodero-Tavoletti, M.; Mishima, K.; Narita, Y.; Cavenee, W.; Furnari, F.; Huang, H.-J.S.; Tiganis, T. The protein tyrosine phosphatase TCPTP suppresses the tumorigenicity of glioblastoma cells expressing a mutant epidermal growth factor receptor. J. Biol. Chem., 2001, 276, 46313-46318.
33. Mishima, K.; Johns, T.; Luwor, R.; Scott, A.; Stockert, E.; Jungbluth, A.; Ji, X.; Suvarna, P.; Voland, J.; Old, L.; Huang, H.; Cavenee, W. Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor. Cancer Res., 2001, 61, 5349-5354.
34. Ashley, D.; Sampson, J.; Archer, G.; Batra, S.; Bigner, D.; Hale, L. A genetically modified allogeneic cellular vaccine generates MHC class I-restricted cytotoxic responses against tumor-associated antigens and protects against CNS tumors in vivo. J. Neuroimmunol., 1997, 78, 34-46.
35. Heimberger, A.; Crotty, L.; Archer, G.; Hess, K.; Wikstrand, C.; Friedman, A.; Friedman, H.; Bigner, D.; Sampson, J. Epidermal growth factor receptor vIII peptide vaccination is efficacious against established intracerebral tumors. Clin. Cancer Res., 2003, 9, 4247-4254.
36. Sampson, J.; Heimberger, A.; Archer, G.; Aldape, K.; Friedman, A.; Friedman, H.; Gilbert, M.; Herndon, J.E. 2nd; McLendon, R.; Mitchell, D.; Reardon, D.; Sawaya, R.; Schmittling, R.; Shi, W.; Vredenburgh, J.; Bigner, D. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J. Clin. Oncol., 2010, 28, 4722-4729.
37. Heimberger, A.; Archer, G.; Mitchell, D.; Bigner, D.; Schmittling, R.; Herndon, J.E. 2nd; Davis, T.; Friedman, H.; Keler, T.; Reardon, D.; Sampson, J. Epidermal growth factor receptor variant III (EGFRvIII) vaccine (CDX-110) in GBM. J. Clin. Oncol., 2009, 27, No. 15 S, abs. 2021.
38. Lal, A.; Glazer, C.; Martinson, H.; Friedman, H.; Archer, G.; Sampson, J.; Riggins, G. Mutant epidermal growth factor receptor up-regulates molecular effectors of tumor invasion. Cancer Res., 2002, 62, 3335-3339.
39. Griffero, F.; Daga, A.; Marubbi, D.; Capra, M.; Melotti, A.; Pattarozzi, A.; Gatti, M.; Bajetto, A.; Porcile, C.; Barbieri, F.; Favoni, R.; Lo Casto, M.; Zona, G.; Spaziante, R.; Florio, T.; Corte, G. Different response of human glioma tumor-initiating cells to epidermal growth factor receptor kinase inhibitors. J. Biol. Chem., 2003, 284, 7138-7148.
40. Halatsch, M.-E.; Gehrke, E.; Vougioukas, V.; Bötefür, I.; Efferth, T.; Gebhardt, E.; Domhof, S.; Schmidt, U.; Buchfelder, M. Inverse correlation of epidermal growth factor receptor messenger RNA induction and suppression of anchorage-independent growth by OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in glioblastoma multiforme cell lines. J. Neurosurg., 2004, 100, 523-533.
41. Prados, M.; Lamborn, K.; Chang, S.; Burton, E.; Butowski, N.; Malec, M.; Kapadia, A.; Rabbitt, J.; Page, M.; Fedoroff, A.; Xie, D.; Kelley, S. Phase I study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma. Neurooncol., 2006, 8, 67-78.
42. Krishnan, S.; Brown, P.; Ballmann, K.; Fiveash, J.; Uhm, J.; Giannini, C.; Jaeckle, K.; Geoffroy, F.; Nabors, L.; Buckner, J. Phase I trial of erlotinib with radiation therapy in patients with glioblastoma multiforme: results of north central cancer treatment group protocol N0177. Int. J. Radiat. Oncol. Biol. Phys., 2006, 65, 1192-1199.
43. Stupp, R.; Hegi, M.; van den Bent, M.; Mason, W.; Weller, M.; Mirimanoff, R.; Cairncross, J. Changing paradigms - An update on the multidisciplinary management of malignant glioma. Oncologist, 2006, 11, 165-180.
44. Raizer, J.; Abrey, L.; Lassman, A.; Chang, S.; Lamborn, K.; Kuhn, J.; Yung, W.; Gilbert, M.; Aldape, K.; Wen, P.; Fine, H.; Mehta, M.; DeAngelis, L.; Lieberman, F.; Cloughesy, T.; Robins, H.; Dancey, J.; Prados, M. A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. Neurooncol., 2010, 12, 95-103.
45. Yung, W.; Vredenburgh, J.; Cloughesy, T.; Nghiemphu, P.; Klencke, B.; Gilbert, M.; Reardon, D.; Prados, M. Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II openlabel study. Neurooncol., 2010, 12, 1061-1070.
46. van den Bent, M.; Brandes, A.; Rampling, R.; Kouwenhoven, M.; Kros, J.; Carpentier, A.; Clement, P.; Frenay, M.; Campone, M.; Baurain, J.; Armand, J.; Taphoorn, M.; Tosoni, A.; Kletzl, H.; Klughammer, B.; Lacombe, D.; Gorlia, T. Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. J. Clin. Oncol., 2009, 27, 1268-1274.
47. Brown, P.; Krishnan, S.; Sarkaria, J.; Wu, W.; Jaeckle, K.; Uhm, J.; Geoffroy, F.; Arusell, R.; Kitange, G.; Jenkins, R.; Kugler, J.; Morton, R.; Rowland, K.; Mischel, P.; Yong, W.; Scheithauer, B.; Schiff, D.; Giannini, C.; Buckner, J. Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: north central cancer treatment group study N0177. J. Clin. Oncol., 2008, 26, 5603-5609.
48. Mirimanoff, R.; Gorlia, T.; Mason, W.; van den Bent, M.; Kortmann, R.-D.; Fisher, B.; Reni, M.; Brandes, A.; Curschmann, J.; Villa, S.; Cairncross, G.; Allgeier, A.; Lacombe, D.; Stupp, R. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. J. Clin. Oncol., 2006, 24, 2563-2569.
49. Prados, M.; Chang, S.; Butowski, N.; DeBoer, R.; Parvataneni, R.; Carliner, H.; Kabuubi, P.; Ayers-Ringler, J.; Rabbitt, J.; Page, M.; Fedoroff, A.; Sneed, P.; Berger, M.; McDermott, M.; Parsa, A.; Vandenberg, S.; James, C.; Lamborn, K.; Stokoe, D.; Haas-Kogan, D. Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. J. Clin. Oncol., 2009, 27, 579-584.
50. Peereboom, D.; Shepard, D.; Ahluwalia, M.; Brewer, C.; Agarwal, N.; Stevens, G.; Suh, J.; Toms, S.; Vogelbaum, M.; Weil, R.; Elson, P.; Barnett, G. Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme. J. Neurooncol., 2010, 98, 93-99.
51. Wang, M.; Lu, K.; Zhu, S.; Dia, E.; Vivanco, I.; Shackleford, G.; Cavenee, W.; Mellinghoff, I.; Cloughesy, T.; Sawyers, C.; Mischel, P. Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTENdeficient and PTEN-intact glioblastoma cells. Cancer Res., 2006, 66, 7864-7869.
52. Fan, Q.-W.; Cheng, C.; Nicolaides, T.; Hackett, C.; Knight, Z.; Shokat, K.; Weiss, W. A dual phosphoinositide-3-kinase alpha/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma. Cancer Res., 2007, 67, 7960-7965.
53. Doherty, L.; Gigas, D.; Kesari, S.; Drappatz, J.; Kim, R.; Zimmermann, J.; Ostrowsky, L.; Wen, P. Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas. Neurology, 2006, 67, 156-158.
54. Reardon, D.; Desjardins, A.; Vredenburgh, J.; Gururangan, S.; Friedman, A.; Herndon, J.E. 2nd; Marcello, J.; Norfleet, J.; McLendon, R.; Sampson, J.; Friedman, H. Phase II trial of erlotinib plus sirolimus in adults with recurrent glioblastoma. J. Neurooncol., 2010, 96, 219-230.
55. Prados, M.; Warnick, R.; Mack, E.; Chandler, K.; Rabbitt, J.; Page, M.; Malec, M. Intravenous carboplatin for recurrent gliomas: a dose-escalating phase II trial. Am. J. Clin. Oncol., 1996, 19, 609-612.
56. de Groot, J.; Gilbert, M.; Aldape, K.; Hess, K.; Hanna, T.; Ictech, S.; Groves, M.; Conrad, C.; Colman, H.; Puduvalli, V.; Levin, V.; Yung, W. Phase II study of carboplatin and erlotinib (tarceva, OSI-774) in patients with recurrent glioblastoma. J. Neurooncol., 2008, 90, 89-97.
57. Heath, V.L.; Bicknell, R. Anticancer strategies involving the vasculature. Nat. Rev. Clin Oncol., 2009, 6, 395-404.
58. Hasselbalch, B.; Lassen, U.; Hansen, S.; Holmberg, M.; Sorensen, M.; Kosteljanetz, M.; Broholm, H.; Stockhausen, M.-T.; Poulsen, H. Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial. Neurooncol., 2010, 12, 508-516.
59. Sathornsumetee, S.; Desjardins, A.; Vredenburgh, J.; McLendon, R.; Marcello, J.; Herndon, J.E. 2nd; Mathe, A.; Hamilton, M.; Rich Sr, J.; Norfleet, J.; Gururangan, S.; Friedman, H.; Reardon, D. Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma. Neurooncol., 2010, 12, 1300-1310.
60. Lassman, A.; Rossi, M.; Raizer, J.; Razier, J.; Abrey, L.; Lieberman, F.; Grefe, C.; Lamborn, K.; Pao, W.; Shih, A.; Kuhn, J.; Wilson, R.; Nowak, N.; Cowell, J.; DeAngelis, L.; Wen, P.; Gilbert, M.; Chang, S.; Yung, W.; Prados, M.; Holland, E. Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01. Clin. Cancer Res., 2005, 11, 7841-7850.
61. Jackman, D.M.; Yeap, B.Y.; Sequist, L.V. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin. Cancer Res., 2006, 12, 3908-3914.
62. Cataldo, V.D.; Gibbons, D.L.; Perez-Soler, R.; Quintas-Cardama, A. Treatment of non-small cell lung cancer with erlotinib or gefitinib. N. Engl. J. Med., 2011, 364, 947-955.
63. Stommel, J.; Kimmelman, A.; Ying, H.; Nabioullin, R.; Ponugoti, A.; Wiedemeyer, R.; Stegh, A.; Bradner, J.; Ligon, K.; Brennan, C.; Chin, L.; DePinho, R. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science, 2007, 318, 287-290.
64. Comoglio, P.; Giordano, S.; Trusolino, L. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat. Rev. Drug Discov., 2008, 7, 504-516.
65. Weinstein, I. Cancer. Addiction to oncogenes - the Achilles heal of cancer. Science, 2002, 297, 63-64.
66. Marusyk, A.; Polyak, K. Tumor heterogeneity: causes and consequences. Biochem. Biophys. Acta, 2010, 1805, 105-117.
67. Halatsch, M.-E.; Löw, S.; Mursch, K.; Hielscher, T.; Schmidt, U.; Unterberg, A.; Vougioukas, V.; Feuerhake, F. Candidate genes for sensitivity and resistance of human glioblastoma multiforme cell lines to erlotinib. J. Neurosurg., 2009, 111, 211-218.
68. Cloughesy, T.; Mischel, P. New strategies in the molecular targeting of glioblastoma: how do you hit a moving target? Clin. Cancer Res., 2011, 17, 6-11.